R. Alten

418 total citations
19 papers, 259 citations indexed

About

R. Alten is a scholar working on Rheumatology, Pharmacology and Nephrology. According to data from OpenAlex, R. Alten has authored 19 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Rheumatology, 5 papers in Pharmacology and 3 papers in Nephrology. Recurrent topics in R. Alten's work include Rheumatoid Arthritis Research and Therapies (9 papers), Systemic Lupus Erythematosus Research (5 papers) and Gout, Hyperuricemia, Uric Acid (3 papers). R. Alten is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (9 papers), Systemic Lupus Erythematosus Research (5 papers) and Gout, Hyperuricemia, Uric Acid (3 papers). R. Alten collaborates with scholars based in Germany, United States and United Kingdom. R. Alten's co-authors include Sławomir Jeka, Erika Gromnica‐Ihle, Klaus Krueger, Stanisław Sierakowski, Frank Buttgereit, Jacek Szechiński, Gabriele Doering, Winfried Häuser, Frank Petzke and Eva Winter and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Value in Health.

In The Last Decade

R. Alten

16 papers receiving 240 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Alten Germany 6 100 73 60 32 28 19 259
T. Lightfoot Germany 3 154 1.5× 76 1.0× 39 0.7× 24 0.8× 17 0.6× 3 399
Barbara Incorvaia Italy 3 98 1.0× 55 0.8× 36 0.6× 44 1.4× 37 1.3× 5 404
Steven Schwid United States 8 86 0.9× 53 0.7× 30 0.5× 28 0.9× 48 1.7× 10 424
M. Hedman Sweden 13 65 0.7× 21 0.3× 15 0.3× 26 0.8× 7 0.3× 20 417
G. Littlejohn Australia 7 140 1.4× 143 2.0× 142 2.4× 23 0.7× 52 1.9× 11 368
Ana Paula Santin Brazil 8 18 0.2× 88 1.2× 17 0.3× 8 0.3× 63 2.3× 12 382
Luca Ausili Cefaro Italy 7 22 0.2× 22 0.3× 205 3.4× 72 2.3× 11 0.4× 10 416
Tang Jiang China 11 28 0.3× 28 0.4× 11 0.2× 71 2.2× 8 0.3× 21 415
Johannes Achenbach Germany 9 16 0.2× 34 0.5× 20 0.3× 48 1.5× 10 0.4× 21 405
Jesús M. Cesar Spain 13 36 0.4× 59 0.8× 31 0.5× 8 0.3× 155 5.5× 32 478

Countries citing papers authored by R. Alten

Since Specialization
Citations

This map shows the geographic impact of R. Alten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Alten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Alten more than expected).

Fields of papers citing papers by R. Alten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Alten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Alten. The network helps show where R. Alten may publish in the future.

Co-authorship network of co-authors of R. Alten

This figure shows the co-authorship network connecting the top 25 collaborators of R. Alten. A scholar is included among the top collaborators of R. Alten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Alten. R. Alten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Besuyen, R., Arthur Kavanaugh, René Westhovens, et al.. (2020). P525 Rheumatoid arthritis treatment with filgotinib: Week 156 safety and efficacy data from a phase 2b open-label extension study. Journal of Crohn s and Colitis. 14(Supplement_1). S452–S452. 3 indexed citations
3.
Khan, Nasim A., Horace J. Spencer, Elena Nikiphorou, et al.. (2017). Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study. Lara D. Veeken. 56(8). 1395–1400. 3 indexed citations
4.
Alten, R., B. Haraoui, Manon Truchon, et al.. (2017). FRI0128 Prism – pictorial representation of illness and self measure: the use of a simple non-verbal tool as a patient-centred outcome measure in early rheumatoid arthritis cohorts. Annals of the Rheumatic Diseases. 76. 529–529. 3 indexed citations
5.
Bartlett, Susan J., Bruno Fautrel, Françis Guillemin, et al.. (2017). SAT0132 The rheumatoid arthritis flare questionnaire (RA-FQ): results of rasch analysis and feedback on real-world applications from international RA patients and clinicians. Annals of the Rheumatic Diseases. 76. 818–819.
6.
7.
8.
9.
Sommer, Claudia, Winfried Häuser, R. Alten, et al.. (2012). Medikamentöse Therapie des Fibromyalgiesyndroms. Der Schmerz. 26(3). 297–310. 55 indexed citations
10.
Schlesinger, Naomi, R. Alten, Thomas Bardin, et al.. (2012). FRI0369 Effect of canakinumab vs triamcinolone acetonide for treatment of gouty arthritis in patients who are unable to use nsaids and colchicine or with severe gouty arthritis. Annals of the Rheumatic Diseases. 71. 439–439. 1 indexed citations
11.
Alten, R., Mark Bloch, Thomas Bardin, et al.. (2012). AB1081 Efficacy and safety of canakinumab vs triamcinolone acetonide in persistent or elderly gouty arthritis patients. Annals of the Rheumatic Diseases. 71. 700–700. 2 indexed citations
12.
Detert, J., H. Bastian, Joachim Listing, et al.. (2012). OP0145 Induction therapy with adalimumab plus methotrexate versus methotrexate monotherapy in recent onset rheumatoid arthritis (RA) – an investigator initiated randomized controlled trial. Annals of the Rheumatic Diseases. 71. 102–103. 1 indexed citations
13.
Häuser, Winfried, Steven E. Schild, R. Alten, et al.. (2010). Validierung der deutschen Version der regionalen Schmerzskala zur Diagnose des Fibromyalgiesyndroms. Der Schmerz. 24(3). 226–235. 28 indexed citations
14.
Buttgereit, Frank, Gabriele Doering, Stanisław Sierakowski, et al.. (2010). Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Annals of the Rheumatic Diseases. 69(7). 1275–1280. 86 indexed citations
15.
Alten, R., Cristiano A. F. Zerbini, Sławomir Jeka, et al.. (2009). Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Annals of the Rheumatic Diseases. 69(2). 364–367. 49 indexed citations
16.
17.
Wollenhaupt, J., R. Alten, Harald Burkhardt, et al.. (2006). [Current therapeutic strategy for rheumatoid arthritis].. PubMed. 148(42). 38–42; quiz 43. 3 indexed citations
18.
Schneider, M., M. Lelgemann, Christoph Baerwald, et al.. (2004). Nutzen der station�ren Therapie in der Versorgung von Patienten mit Rheumatoider Arthritis. Zeitschrift für Rheumatologie. 63(5). 402–413. 5 indexed citations
19.
Zeidler, H, et al.. (2004). Wirksame Schmerztherapie mit Tilidin/Naloxon retard bei Patienten mit Rheumatoider Arthritis (RA). Aktuelle Rheumatologie. 29(1). 35–39. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Lightfoot Breakdown of academic impact, for papers by Barbara Incorvaia Breakdown of academic impact, for papers by Steven Schwid Breakdown of academic impact, for papers by M. Hedman Breakdown of academic impact, for papers by G. Littlejohn Breakdown of academic impact, for papers by Ana Paula Santin Breakdown of academic impact, for papers by Luca Ausili Cefaro Breakdown of academic impact, for papers by Tang Jiang Breakdown of academic impact, for papers by Johannes Achenbach Breakdown of academic impact, for papers by Jesús M. Cesar
Rankless by CCL
2026